Medicare Coverage For Non-IND Drug Trials Should Continue – PhRMA & BIO
Executive Summary
The drug industry is pushing for continued Medicare coverage of pharmaceutical research that is not subject to the FDA's investigational new drug requirements as CMS begins to revise its Medicare clinical trials policy
You may also be interested in...
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule
Clinical Trials Can Charge For Using Competitor Drugs Under FDA Proposed Rule
Clinical trial sponsors are permitted to charge for approved drugs obtained from competitors while conducting a clinical study evaluating an investigational drug under an FDA proposed rule
CMS Splits Coverage With Evidence Development Into Two Categories
Medicare is offering added flexibility to pay for research-related expenses that arise in the clinical trials conducted for a Part B national coverage decision, under revisions to Medicare's coverage with evidence development policy, released July 12